Immunocore Holdings plc - ADR
IMCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.47B
Close$
$-21.06
173.5% downside
Current Fair Value
173.5% downsideOvervalued by 173.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.47 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.74 |
| Outstanding Shares | 50,754,763 |
Return
| Return on Equity | -4.78% |
|---|---|
| Return on Assets | -1.76% |
| Return on Invested Capital | -2.93% |
Valuation & Multiples
| P/E Ratio | -77.91 |
|---|---|
| PEG | -49.24 |
| Price to Sales | 4.09 |
| Price to Book Ratio | 4.09 |
| Enterprise Value to Revenue | 2.74 |
| Enterprise Value to EBIT | -43.44 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$146.25 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$146.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 8.6483▲ 788.97% |
|---|---|
| Total Calls | 190,200▲ 55.65% |
| Total Puts | 1,644,900▲ 1674.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.07%▲ 1.79% |
|---|---|
| Total Invested | $1.58B▼ 11.67% |
| Investors Holding | 153▼ 6.00% |
ESG Score
No data
About Immunocore Holdings plc
2,020 employeesImmunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...